Metabolicheskiy sindrom: terapevticheskie vozmozhnosti i perspektivy


Cite item

Full Text

Abstract

Интерес врачей разных специальностей к симптомокомплексу, получившему название “метаболический синдром” (МС), все более возрастает по мере изучения этого феномена. Патогенез, клинические проявления, принципы лечения МС остаются предметом исследований и дискуссий в медицинском научном мире. Сегодня распространенность МС можно считать эпидемией – этим недугом страдает около 25% взрослого населения

About the authors

V. S Zadionchenko

Московский государственный медико-стоматологический университет

T. V Adasheva

Московский государственный медико-стоматологический университет

O. Yu Demicheva

Московский государственный медико-стоматологический университет

O. N Poryvkina

Московский государственный медико-стоматологический университет

References

  1. Ford E.S et al. Prevalence of the metabolic syndrome among US adults. JAMA 2002; 356–9.
  2. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10–14, 2005;San Diego, California. Presented June 12, 2005.
  3. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–9.
  4. Cleary P, Orchard T, Zinman B et al. Coronary calcification in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort for the DCCT/EDIC study group. Program and abstracts of the American Diabetes Association 63rd Annual Scientific Sessions; June 13–17, 2003;New Orleans, Louisiana.
  5. Khaw K.T, Wareham N, Bingham S et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413–20.
  6. Hamman R. Late - breaking trials. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10–14, 2005; San Diego, California. Presented June 12, 2005.
  7. Barclay L. Medscape Medical News. New definition of the metabolic syndrome: a newsmaker interview with Sir George Alberti M.A, D Phil, B.M.B.Ch. Available at: http://www.medscape.com/viewarticle/504382 Accessed July 8, 2005.
  8. Lindstrьm J, Louheranta A, Mannelin M. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabet Care 2003; 26: 3230–6.
  9. Am. College of Physicians. The effect of diet and exercise or Metformin on the metabolic syndrome. AHJ 2005; 142 (8): 1–42.
  10. Dansinger M.L, Gleason J.A, Griffith J.L et al. Research Laboratory, Tufts-New England Medical Center, Boston, Mass 02111 Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. Division of Endocrinology, Diabetes, and Metabolism Atherosclerosis, USA.
  11. Targerson J.S. XENDOS – a Unique Advantage Abstract Book Satellite Symp, May 2003, Helsinki.
  12. Scheen A. Late breaking clinical trials. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10–14, 2005; San Diego, California.
  13. Sethi J.K, Vidal-Puid A. Visfatin: the missing link between intra - abdominal obesity and diabetes? Trend Mol Med 2005 Aug; 11 (8): 344–7.
  14. Kendall D.M, Kim D, Poon T et al. Improvements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 weeks. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10–14, 2005; San Diego, California.
  15. Chiasson J.L, Josse R.G, Gomis R et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 Jul 23; 290 (4): 486–94.
  16. Califf R.M. Insulin resistance: a global epidemic in need of effective therapies. Eur Heart J 2003; 5: 13–8.
  17. Hetzel J et al. Rapid effects of Rosiglitazone treatment of endothelial function and inflammatory biomarkers. Departament of Endocrinology and Metabolism, University of Ulm, Germany. 2005. Reprint.
  18. Fagerberg B et al. Tesaglitazar, a novel dual peroxisome proliferator - activated receptor alpha/gamma agonist, dose - dependently improves the metabolic abnormalities associated with insulin resistance in a non - diabetic population. Wallenberg Laboratory for cardiovascular research, Sweeden. 2005. Reprint.
  19. Diabetes rates and b - cell function in the pioglitazone in prevention of diabetes (PIPOD) study. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10–14, 2005; San Diego, California.
  20. Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. Hypertens 2003; 21: 1011–53.
  21. Punzi H.A et al. Antyhypertensive and Lipid – Lowering Heart Attack Treal Study;Trinity Hypertension Research Institute. Metabolic issues in the Antihypertensive and Lipid- Lowering Heart Attack Treal Study. Curr Hypertens Rep 2004; 6: 106–10.
  22. van Zwieten P.A. The metabolic syndrome – a therapeutic challenge. University of Amsterdam. 2005.
  23. Mancia G et al. Outcomes with nifedipine GITS of coamilozide in hypertensive diabetes and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension 2003; 41: 431–6.
  24. HOPE study. N Engl J Med 2000; 342: 145–53.
  25. Sun Y, Ratajska A, Weber K.T. Inhibition of angiotensin - converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J Lab Clin Med 1995; 126: 95–101.
  26. Nielsen F.S, Rossing P, Ali S et al. Effects of lisinopril and atenolol on left ventricular mass in hypertensive type 2 (noninsulin - dependent) diabetic patients with diabetic nephropathy (abstract). Am J Hypertens 1994; 7: 40A.
  27. Handa S, Hamada M, Ura M et al. Regression of increased left ventricular masses in elderly hypertensive patients on lisinopril as assessed by magnetic resonance imaging. Acad Radiol 1996; 3: 294–9.
  28. Kawahara J, Hsieh S.T, Tanaka S et al. Effects of lisinopril on lipid peroxidation, cell membrane fatty acids, and insulin sensitivity in essential hypertension with impaired glucose tolerance (abstract). Am J Hypertens 1994; 7: 23A.
  29. Slishko E. Influence of lisinopril on blood coagulation and fibrinolysis in hypertensive patients of different age (abstract). Eur Heart J 1994 Aug; 15 (Suppl.): 195.
  30. Gillis C.N, Chen X, Merker M.M. Lisinopril and ramiprilat protection of the vascular endothelium against free radical - induced functional injury. J Pharmacol Exp Ther 1992; 262: 212–6.
  31. Virdis A, Mattel P, Ghiadoni L et al. Effect of lisinopril on endothelial function in hypertensive patients (abstract). Am J Hypertens 1995; 8: 178.
  32. Reisin E et al. Lisinopril versus HCTZ in obese hypertensive patients: a multicenter placebo - controlled trial. Treatment in obese Patients with Hypertension (TROPHY) Study Group. Hypert 1997; Jul 30: 140–5.
  33. Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regiments based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022–31.
  34. Lindholm L.H et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the antihypertensive treatment and lipid profile in a North of Sweden efficacy evalution (ALPINE) study. О Hypertens 2003; 21: 1563–74.
  35. Mogensen C.E. New concepts in blood pressure - lowing management in diabetic patients: the case for early ACE inhibitor combination therapy with diuretics. ОA Human Hypertension. 2005; 19: 15–20.
  36. Vitale S et al. “Metabolic effect of Telmisartan and Losartan in Hypertensive patients with Metabolic syndrome.” 2005. Reprint.
  37. Бенсон С. и др. Телмисартан – блокатор ангиотензиновых рецепторов, способный стимулировать PPARg - рецепторы. Сб.: Лечение артериальной гипертонии и метаболических нарушений: новые данные. М.: Практика, 2005.
  38. Дероза Г. и др. Влияние телмисартана и эпросартана на обмен глюкозы и липидный профиль у больных инсулиннезависимым сахарным диабетом и артериальной гипертонией. Сб.: Лечение артериальной гипертонии и метаболических нарушений: новые данные. М.: Практика, 2005.
  39. Розано Г.М. и др. Сравнение влияния телмисартана и лосартана на обмен глюкозы у больных артериальной гипертонией и метаболическим синдромом. Сб.: Лечение артериальной гипертонии и метаболических нарушений: новые данные. М.: Практика, 2005.
  40. Opie L.H et al. Old antihypertensives and new diabets. J Hypertens 2004; 22: 1453–8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2005 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).